サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1572619

ナトリウムグルコースコトランスポーター2（SGLT2）阻害剤の世界市場レポート 2024年

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2024

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.57円
ナトリウムグルコースコトランスポーター2（SGLT2）阻害剤の世界市場レポート 2024年
出版日: 2024年10月17日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR8.7％で141億9,000万米ドルに成長します。予測期間中に予想される成長は、糖尿病有病率の増加、肥満率の上昇、糖尿病管理に対する意識の高まり、心臓病や腎臓病の治療におけるSGLT2阻害薬の使用拡大など、いくつかの要因に起因しています。この期間を形成すると予想される主な動向には、併用療法の統合、個別化医療へのアプローチ、技術の進歩、従来の薬物治療における継続的な発展が含まれます。

ナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場は、糖尿病有病率の上昇により拡大すると予測されます。糖尿病は、インスリン分泌、インスリン作用、またはその両方の問題から生じる高血糖を特徴とする代謝疾患群です。糖尿病患者増加の要因としては、都市化、ストレス、環境汚染物質、ヘルスケアサービスへの不十分なアクセスなどが挙げられます。SGLT2阻害薬は、腎臓におけるグルコースの再吸収を阻害することにより血糖値を下げ、尿中への排泄を促すことで糖尿病の治療に使用されます。さらに、これらの阻害剤は心血管系および腎臓に利点をもたらすため、糖尿病およびその合併症を管理するための重要な選択肢となっています。国際糖尿病連合は2021年7月、糖尿病患者数が2030年には6億4,300万人、2045年には7億8,300万人に達し、その4分の3が低・中所得国に居住すると予測していると報告しました。このような糖尿病有病率の増加が、SGLT2阻害薬市場の拡大に拍車をかけています。

SGLT2阻害薬市場の主要企業は、患者の転帰と血糖管理を強化するために、二重阻害薬療法の開発に注力しています。二重阻害薬治療は、ナトリウムグルコースコトランスポーター1および2（SGLT1およびSGLT2）の両方を標的とし、心不全や糖尿病などの症状に対する治療効果を改善します。例えば、2023年5月、米国のバイオ医薬品会社Lexicon Pharmaceuticals Inc.は、新規のSGLT1とSGLT2のデュアル阻害剤であるソタグリフロジンのFDA承認を取得しました。本剤は、1日1回投与で、心不全、2型糖尿病、慢性腎臓病およびその他の心血管危険因子を有する成人における心血管死、心不全による入院および心不全による緊急受診を減少させる。ソタグリフロジンは、腎臓でのグルコースおよびナトリウムの再吸収を抑制することにより、前負荷および後負荷を減少させ、交感神経の活動を低下させます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界のナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場：促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場の実績：規模と成長, 2018-2023
  • 世界のナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場の予測：規模と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

  • 世界のナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場：タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • インボカナ
  • ジャディアンス
  • ファルシーガまたはフォシーガ
  • スーグラ
  • 世界のナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場：投与経路別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 経口投与
  • その他の投与経路
  • 世界のナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場：エンドユーザー別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 病院
  • ホームケア設定
  • クリニック

第7章 地域別・国別分析

  • 世界のナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場：地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
  • 世界のナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場：国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場：競合情勢
  • ナトリウムグルコースコトランスポーター2（SGLT2）阻害剤市場：企業プロファイル
    • Pfizer Inc.
    • Johnson & Johnson Inc.
    • Merck & Co. Inc.
    • Bayer AG
    • Sanofi S.A.

第31章 その他の大手企業と革新的企業

  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmBH
  • Astellas Pharma Inc
  • Daiichi Sankyo Company Limited
  • Sun Pharmaceutical Industries Ltd
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Taisho Pharmaceutical Holdings Co. Ltd.
  • Lupin Limited
  • Glenmark pharmaceuticals
  • Torrent Pharmaceuticals Ltd
  • Mankind Pharma Ltd
  • Kissei Pharmaceutical Co. Ltd.
  • Patsnap Synapse

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r19787

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs designed to manage type 2 diabetes by blocking the SGLT2 protein in the kidneys. This action prevents the reabsorption of glucose, leading to its excretion in the urine and helping to lower blood glucose levels. In addition to their role in controlling blood sugar, SGLT2 inhibitors can aid in weight loss and lower blood pressure, and they offer additional cardiovascular and renal benefits, which are valuable for managing diabetic complications.

The main types of SGLT2 inhibitors include Invokana, Jardiance, Farxiga (or Forxiga), and Suglat. Invokana is a prescription medication used to reduce blood sugar levels in adults with type 2 diabetes. These medications are generally administered orally and are utilized by various end users such as hospitals, homecare settings, and clinics.

The sodium glucose cotransporter 2 (SGLT 2) inhibitors market research report is one of a series of new reports from The Business Research Company that provides sodium glucose cotransporter 2 (SGLT 2) inhibitors market statistics, including the sodium glucose cotransporter 2 (SGLT 2) inhibitors industry's global market size, regional shares, competitors with a sodium glucose cotransporter 2 (SGLT 2) inhibitors market share, detailed sodium glucose cotransporter 2 (SGLT 2) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the sodium glucose cotransporter 2 (SGLT 2) inhibitors industry. This sodium glucose cotransporter 2 (SGLT 2) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market size has grown strongly in recent years. It will grow from $9.37 billion in 2023 to $10.17 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth observed during the historic period can be attributed to several factors, early successes in clinical trials, increasing regulatory approvals, a rise in diabetes diagnosis rates, and a growing demand for innovative treatments for diabetes.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $14.19 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The anticipated growth during the forecast period can be attributed to several factors, the increasing prevalence of diabetes, rising obesity rates, greater awareness of diabetes management, and the expanding use of SGLT2 inhibitors in treating heart and kidney diseases. Key trends expected to shape this period include the integration of combination therapies, personalized medicine approaches, advancements in technology, and ongoing developments in traditional drug treatments.

The sodium glucose cotransporter 2 (SGLT2) inhibitor market is projected to expand due to the rising prevalence of diabetes. Diabetes is a group of metabolic disorders marked by high blood sugar levels, which arise from issues with insulin secretion, insulin action, or both. Factors contributing to the increase in diabetes cases include urbanization, stress, environmental pollutants, and inadequate access to healthcare services. SGLT2 inhibitors are used to treat diabetes by lowering blood glucose levels through preventing glucose reabsorption in the kidneys, leading to its excretion in urine. Additionally, these inhibitors provide cardiovascular and renal benefits, making them an important option for managing diabetes and its complications. The International Diabetes Federation reported in July 2021 that the number of people living with diabetes is expected to reach 643 million by 2030 and 783 million by 2045, with three-quarters of these individuals residing in low- and middle-income countries. This growing prevalence of diabetes is fueling the expansion of the SGLT2 inhibitor market.

Leading companies in the SGLT2 inhibitor market are focusing on developing dual inhibitor therapies to enhance patient outcomes and blood sugar management. Dual inhibitor therapies target both sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) to improve treatment efficacy for conditions such as heart failure and diabetes. For example, in May 2023, Lexicon Pharmaceuticals Inc., a U.S.-based biopharmaceutical firm, received FDA approval for sotagliflozin, a novel dual SGLT1 and SGLT2 inhibitor. This once-daily tablet is designed to reduce cardiovascular death, hospitalizations for heart failure, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Sotagliflozin helps by reducing renal glucose and sodium reabsorption, leading to decreased preload and afterload, as well as reduced sympathetic activity.

In December 2022, Torrent Pharmaceuticals, an India-based pharmaceutical company, formed a partnership with Boehringer Ingelheim International GmbH to co-market diabetes and cardiovascular disease treatments. This collaboration aims to develop solutions for glycemic control in adults with type 2 diabetes mellitus. Empagliflozin, a product of this partnership, not only reduces the risk of cardiovascular death in individuals with type 2 diabetes and cardiovascular disease but also lowers the risk of cardiovascular death and hospitalizations for heart failure in adults with heart failure. Boehringer Ingelheim International GmbH, a Germany-based pharmaceutical company, specializes in developing and manufacturing health products for humans and animals.

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki pharmaceutical Co Ltd.

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market consists of sales of luseogliflozin, remogliflozin, tofogliflozin and sergliflozin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sodium glucose cotransporter 2 (SGLT2) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sodium glucose cotransporter 2 (SGLT2) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sodium glucose cotransporter 2 (SGLT2) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Invokana; Jardiance; Farxiga Or Forxiga; Suglat
  • 2) By Route Of Administration: Oral Route; Other Route Of Administration
  • 3) By End User: Hospitals; Homecare Settings; Clinics
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Inc.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Characteristics

3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trends And Strategies

4. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size and Growth

  • 5.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Segmentation

  • 6.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Invokana
  • Jardiance
  • Farxiga Or Forxiga
  • Suglat
  • 6.2. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral Route
  • Other Route Of Administrations
  • 6.3. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare Settings
  • Clinics

7. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Regional And Country Analysis

  • 7.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 8.1. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 9.1. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 9.2. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 10.1. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 11.1. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 11.2. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 12.1. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 13.1. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 14.1. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 14.2. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 15.1. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 15.2. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 16.1. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 17.1. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 18.1. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 19.1. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 20.1. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 21.1. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 21.2. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 22.1. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 23.1. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 23.2. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 24.1. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 24.2. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 25.1. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 25.2. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 26.1. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 26.2. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 27.1. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 28.1. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 28.2. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

  • 29.1. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
  • 29.2. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Landscape
  • 30.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi S.A.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Other Major And Innovative Companies

  • 31.1. Bristol-Myers Squibb Company
  • 31.2. AstraZeneca plc
  • 31.3. Eli Lilly and Company
  • 31.4. Boehringer Ingelheim International GmBH
  • 31.5. Astellas Pharma Inc
  • 31.6. Daiichi Sankyo Company Limited
  • 31.7. Sun Pharmaceutical Industries Ltd
  • 31.8. Sumitomo Dainippon Pharma Co. Ltd.
  • 31.9. Taisho Pharmaceutical Holdings Co. Ltd.
  • 31.10. Lupin Limited
  • 31.11. Glenmark pharmaceuticals
  • 31.12. Torrent Pharmaceuticals Ltd
  • 31.13. Mankind Pharma Ltd
  • 31.14. Kissei Pharmaceutical Co. Ltd.
  • 31.15. Patsnap Synapse

32. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Benchmarking

33. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

35. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Future Outlook and Potential Analysis

  • 35.1 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer